Long-Term Liabilities: Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals (PHIO) faces a potential capital shortfall and remains dependent on the test results of its INTASYL system. This price chart on GURU.Markets reflects the asset's dynamics, where the specific long-term debt metric stands at 0.00. The business relies on unique gene-silencing patents that create significant barriers to entry. The company is currently conducting high-tech research into self-delivering molecules to combat tumors.

This indicator captures the total volume of liabilities with a maturity of over one year, determining the degree of financial autonomy and the risk of credit pressure on capital. An analysis of the long-term debt history of Phio Pharmaceuticals (PHIO) allows for an assessment of the company's resilience to Asian supply chain disruptions and patent disputes, confirming the asset's ability to maintain solvency amidst geopolitical instability.